Author: Helen Baxter, Vice President, North Highland
I joined fellow Life Science enthusiasts at the OnHelix conference in Cambridge at the beginning of the month to listen and learn to some of the latest thinking in Innovation in the industry. A range of experts talked about BioInnovation in the pharma and biotech industry at the latest OnHelix conference in Cambridge July 2022. Here are some of the key themes that emerged from the conference.
1. The convergence of technology into Life Sciences companies has critical and long reaching symptoms which are creating new opportunities for…
Sian Steele appointed Chair of the Boards of Howard Investments and Howard Ventures
Andrew Hynard appointed Non-Executive Director
Cambridge, 28th July 2022: Cambridge-based property developer and investor Howard Group is pleased to announce Sian Steele as its new Board Chair.
Sian will take up the position from 1st August after serving for the past two years as a Non-Executive Director of the Group.
Sian is well known in the Cambridge business community having previously worked as a Senior Partner in the Cambridge office for PwC, and has more than 30…
Cpl Life Sciences UK is proud to have been part of the trailblazer groups for the first clinical research apprenticeships in industry – Clinical Trial Specialist degree apprenticeship (Level 6), and the Regulatory Affairs Specialist (Level 7) both launched in 2019. It is part of our ongoing work and commitment to ensure the worsening skills shortages in the UK life sciences sectors are addressed, through proactive initiatives and programmes to bring in new talent and upskill/reskill current workforces. We have always been passionate about ‘giving back’ and have dedicated a…
One Nucleus Summer Life Sciences Dinner, Wednesday 6 July 2022
On the eve of our annual ON Helix Conference, we were pleased to welcome over 100 guests to attend the inaugural One Nucleus Summer Life Sciences Dinner on the stunning grounds of Babraham Research Campus.
The evening began with a networking drinks reception and once seated, Tony Jones, CEO, One Nucleus thanked the sponsors and guests for attending and supporting the evening.
In between courses, names were pulled out of a hat and six lucky winners received a copy of the book, ‘Cambridge per diem’ by Rosie Zanders. In this book,…
Link below to EY blog by Pamela Spence (EY PArtner)
https://www.linkedin.com/pulse/how-you-prioritize-your-supply-chain-inv…
Invited guests enjoyed a look around Nottingham CRO Cellomatics Biosciences’ new lab facilities at Colwick Quays Business Park last week, at a special launch event hosted by the company’s CEO and founder, Dr Shailendra Singh.
Cellomatics moved into the purpose-built premises last month in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services. Representing a three-fold increase in the company’s footprint, the facility covers approximately 5,500 sq ft of space across two levels and allows rooms for further expansion.
Members of the drug…
AMSBIO has expanded its range of antibodies, biomarkers and assay kits related to free radicals (ROS and RNS), non-radical reactive derivatives (or oxidants) and antioxidants for researchers investigating the mechanism of oxidative stress.
It is widely recognized free radicals play a key role in physiological processes including protein phosphorylation as well as activation of transcriptional factors and immunity, but they need to be kept at a low level.
Changes in environmental factors, diet and lifestyle are known to contribute significantly to an increase in free radical production in the…
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services
Cambridge, UK, 19 July 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services. The Company’s laboratory space has been doubled in response to the increasing market demand for OOC services as the technology gains traction within drug…
Press release - Appointments
Macomics Announces New Hires as it Expands its Macrophage-based Drug Discovery and Operations Teams
Edinburgh and Cambridge, UK, 18 July 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made three new appointments to its scientific and operations teams, to support growth and accelerate its R&D.
In the R&D team, Dr Thomas Crozier joins as a Senior Scientist and Dr Yuxin Cui joins as Senior Bioinformatician, with Ms. Lisa Seymour joining as Operations Manager and Health &…
A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumour sample by up to 50 times.
The tool is designed for testing at scale the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, which is effective against many haematological cancers but presents challenges when used to treat solid tumours.
Traditional 2D models that are currently used fail to reproduce the complexity of the tumour’s microenvironment, while models based on patients’ tumours are costly and labour-intensive. The Strathclyde…